Nicotinic acid and the prevention of coronary artery disease

Current Opinion in Lipidology

Volumn 20, Issue 4, 2009, Pages 321-326

  Digby, Janet E ^a   Lee, Justin Ms ^a   Choudhury, Robin P ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cholesteryl ester transfer protein; G protein coupled receptor 109a; Niacin; NIACR1; Nicotinic acid

Indexed keywords

ADIPONECTIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 109A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; HUMANS; NIACIN;

EID: 68449089520     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32832d3b9d     Document Type: Review

References (50)

1. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955; 54:558-559.
2. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255.
3. Scandinavian Simvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
5. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1:16-19.
6. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79:8-15.
7. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998; 82 (12A):74U-81U; discussion 85U-86U.
8. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med 2002; 162:1568-1576.
9. Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000; 160:1177-1184.
10. Carlson LA, Hanngren A. Initial distribution in mice of 3h-labeled nicotinic acid studied with autoradiography. Life Sci 1964; 3:867-871.
11. Soga T, Kamohara M, Takasaki J, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003; 303:364-369.
12. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nat Med 2003; 9:352-355.
13. Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003; 278:9869-9874.
14. Taggart AK, Kero J, Gan X, et al. (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem 2005; 280:26649-26652.
15. Havel RJ. Conversion of plasma free fatty acids into triglycerides of plasma lipoprotein fractions in man. Metabolism 1961; 10:1031-1034.
16. *3Leiden. CETP Mice. Arterioscler Thromb Vasc Biol 2008; 28:2016-2022.
17. Watts GF, Chan DC. Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism. Arterioscler Thromb Vasc Biol 2008; 28:1892-1895.
18. Jin F-Y, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells: implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997; 17:2020-2028.
19. Wang W, Basinger A, Neese RA, et al. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am J Physiol Endocrinol Metab 2001; 280:E540-E547.
20. Ganji SH, Tavintharan S, Zhu D, et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004; 45: 1835-1845.
21. Svedmyr N, Harthon L, Lundholm L. The relationship between the plasma concentration of free nicotinic acid and some of its pharmacologic effects in man. Clin Pharmacol Ther 1969; 10:559-570.
22. Zhang S LH. Kamanna S VS. Zhang S MC, et al. Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL. J Lipid Res 2008; 49:1195-1201.
23. Richman JG, Kanemitsu-Parks M, Gaidarov I, et al. Nicotinic acid receptor agonists differentially activate downstream effectors. J Biol Chem 2007; 282:18028-18036.
24. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103:1057-1063.
25. Bodary PF, Eitzman DT. Adiponectin: vascular protection from the fat? Arterioscler Thromb Vasc Biol 2006; 26:235-236.
26. Westphal S, Borucki K, Taneva E, et al. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 2007; 193:361-365.
27. Plaisance EP, Lukasova M, Offermanns S, et al. Niacin stimulates adiponectin secretion through the GPR109A receptor. Am J Physiol Endocrinol Metab 2009; 296:E549-E558.
28. Digby JE, Dyar OJ, McNeill, E, et al. Anti-inflammatory effects of nicotinic acid: suppression of Fractalkine, RANTES, and MCP-1 and upregulation of adiponectin in 3T3-L1 adipocytes [abstract]. Circulation 2008; 118:S-572.
29. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005; 25:2062-2068.
30. Barandier C, Montani JP, Yang Z. Mature adipocytes and perivascular adipose tissue stimulate vascular smooth muscle cell proliferation: effects of aging and obesity. Am J Physiol Heart Circ Physiol 2005; 289:H1807-H1813.
31. Henrichot E, Juge-Aubry CE, Pernin A, et al. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol 2005; 25:2594-2599.
32. Ganji SH, Qin S, Zhang L, et al. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009; 202:68-75.
33. Kuvin JT, Ramet ME, Patel AR, et al. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002; 144:165-172.
34. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004; 15:659-665.
35. Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004; 67:411-419.
36. Choudhury RP, Lee JM, Greaves DR. Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat Clin Pract Cardiovasc Med 2005; 2:309-315.
37. Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 2006; 103:6682-6687.
38. Lai E, De Lepeleire I, Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 2007; 81:849-857.
39. Deng Q, Frie JL, Marley DM, et al. Molecular modeling aided design of nicotinic acid receptor GPR109A agonists. Bioorg Med Chem Lett 2008; 18:4963-4967.
40. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-1592.
41. Taylor AJ, Kent SM, Flaherty PJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512-3517.
42. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006; 22:2243-2250.
43. Lee JM, Robson MD, Yu LM, et al. High dose modified-release nicotinic acid reduces carotid atherosclerosis: a randomized, placebo-controlled magnetic resonance study [abstract]. Circulation 2008; 118:S-686.
44. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122.
45. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007; 370:153-160.
46. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 1620-1630.
47. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304-1316.
48. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370:1781-1790.
49. Rong JX, Li J, Reis ED, et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 2001; 104:2447-2452.
50. Choudhury RP, Rong JX, Trogan E, et al. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol 2004; 24:1904-1909.